

Attorney Docket No. E1047/20075

**DECLARATION (37 CFR 1.63) AND POWER OF ATTORNEY FOR UTILITY OR DESIGN  
APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

**Title of Invention:** NUCLEIC ACID BINDING ENHANCEMENT BY CONJUGATION WITH  
NUCLEOTIDES, NUCLEOSIDES, BASES AND/OR THEIR ANALOGUES

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☒ The attached application, or  
☐ Application No. \_\_\_\_\_, filed on \_\_\_\_\_,  
as amended on \_\_\_\_\_ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

I hereby appoint the practitioners at Customer No. 03000 as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith. Please change the correspondence address for the above-identified application to Customer No. 03000.



**03000**

PATENT TRADEMARK OFFICE

**FULL NAME OF INVENTOR(S)**

Inventor one: Glen H. Erikson Citizen of: Canada

Signature: *Glen H. Erikson* Date: 21 Feb 2002

Inventor two: Jasmine I. Daksis Citizen of: Canada

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Inventor three: \_\_\_\_\_ Citizen of: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Inventor four: \_\_\_\_\_ Citizen of: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

☐ Additional inventors are being named on \_\_\_\_\_ additional form(s) attached hereto.

Attorney Docket No. E1047/20075

**DECLARATION (37 CFR 1.63) AND POWER OF ATTORNEY FOR UTILITY OR DESIGN  
APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

**Title of Invention:** NUCLEIC ACID BINDING ENHANCEMENT BY CONJUGATION WITH  
NUCLEOTIDES, NUCLEOSIDES, BASES AND/OR THEIR ANALOGUES

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☒ The attached application, or  
☐ Application No. \_\_\_\_\_, filed on \_\_\_\_\_,  
as amended on \_\_\_\_\_ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

I hereby appoint the practitioners at Customer No. 03000 as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith. Please change the correspondence address for the above-identified application to Customer No. 03000.



**03000**

PATENT TRADEMARK OFFICE

**FULL NAME OF INVENTOR(S)**

Inventor one: Glen H. Erikson Citizen of: Canada

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Inventor two: Jasmine I. Daksis Citizen of: Canada

Signature: Jasmine Daksis Date: 21 February, 2002

Inventor three: \_\_\_\_\_ Citizen of: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Inventor four: \_\_\_\_\_ Citizen of: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

☐ Additional inventors are being named on \_\_\_\_\_ additional form(s) attached hereto.

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
PATENT EXAMINING OPERATION

Applicant(s): Glen H. Erikson et al.

Serial No: Group Art Unit:

Filed: February 22, 2002 Examiner:

Att. Docket No.: E1047/20075 Confirmation No.:

For: NUCLEIC ACID BINDING ENHANCEMENT BY CONJUGATION WITH  
NUCLEOTIDES, NUCLEOSIDES, BASES AND/OR THEIR ANALOGUES

**STATEMENT UNDER 37 CFR § 1.821(f)**

Commissioner for Patents  
Washington, DC 20231

Sir:

Pursuant to 37 CFR § 1.821(f), Applicant(s) hereby state that the information recorded in the concurrently filed computer readable form is identical to the concurrently filed written sequence listing.


Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,  
COHEN & POKOTILOV, LTD.

February 22, 2002

Please charge or credit  
our Account No. 03-0075  
as necessary to effect  
entry and/or ensure  
consideration of this  
submission.

By

  
David M. Tener  
Registration No. 37,054  
Customer No. 03000  
(215) 567-2010  
Attorneys for Applicants